Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Ovarian Neoplasms 2Neoplasms 2Leukemia, Myeloid, Chronic-Phase 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Vaping 1Urinary Bladder Neoplasms 1Tobacco Use Disorder 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Neoplasms by Histologic Type 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hematologic Diseases 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 10Drug Therapy 9aflutinib 8Gefitinib 7Radiotherapy 6Docetaxel 6Cisplatin 6anlotinib 5Radiosurgery 5Paclitaxel 5pembrolizumab 4Vinorelbine 4Gemcitabine 4tislelizumab 3icotinib 3apatinib 3HM781-36B 3Erlotinib Hydrochloride 3toripalimab 2spartalizumab 2rezivertinib 2camrelizumab 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × NSCLC × BID protein, human × Clear all
NCT04820023 2025-06-06

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Bridge Biotherapeutics, Inc.

Phase 1/2 Terminated
45 enrolled 19 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡